DOVER, NJ, February 15, 2022 – Casio America, Inc., announced today that the U.S. Food and Drug Administration (FDA) has cleared the DZ-D100 DERMOCAMERA™ and the DZ-S50 scope for skin observation as medical devices. The DZ-D100 and DZ-S50 will be available in the U.S. on Casio America’s e-commerce site by March 2022.
Casio began providing the DZ-D100 in Japan in May 2019. The DZ-D100 was developed in collaboration with dermatology professionals and delivers both standard sized and close-up shots of an affected area with a single unit, and can be used with the D’z IMAGE Viewer, a free downloadable software to manage the captured images.
The Dermocamera DZ-D100 is a camera intended to capture high quality dermoscopic images.
DERMOCAMERA photos and videos can be easily managed on a computer using the D’z IMAGE Viewer application software.
The Dermoscope DZ-S50 is intended to be used to observe skin and skin lesions on the patient’s skins.
Casio obtains U.S. FDA clearance for DERMOCAMERA™ and scope for skin observation, furthering its contribution to medical treatment around the world. Tweet
In March 2020, Casio released the DZ-S50 scope, making skin observation even easier. Medical professionals who have introduced these devices in their practice have provided positive feedback, commenting that these Casio products make it simple to take both ordinary or standard sized and close-up shots without switching lenses and noting the ease of making observations since the unit can capture polarized, non-polarized and UV* photos at the same viewpoint with a single click of the shutter button. Casio has been rolling out these innovative medical devices aggressively in markets outside Japan, starting with the launch in Australia and New Zealand in February 2021, where there are high rates of skin disease among the population.
* A 405 nm safelight wavelength is used.
The marketing of certain medical devices in the U.S. requires FDA clearance. The DZ-D100 and DZ-S50 have received FDA Class I clearance. Class I medical devices are devices with low or moderate risk to patient health and safety.
Casio will continue expanding and developing its medical device business both in and outside Japan, seeking to contribute to medical treatment around the world.